+ Watch TSPT
on My Watchlist
How low can you go, Transcept? No matter how low the bar drops, Transcept always seems to manage to limbo under it. The latest level broken is 4, and the market cap of 74M is now substantially less than the December 2012 cash of 85M. That's no guarantee of a rebound - just look to Vanda or Myrexis or Targacept for examples to stocks that hit cash value and kept dropping. I've profited from the first two and lost an equal amount on the last, so I'm a wash on those particular cash plays. Nevertheless, I'm still fascinated by the scenario and I'll risk my score leadership here to see if Transcept can generate a little optimism before getting sucked into the abyss.
Since they raised back in April at $9.00 this must be free money at 5.28. ; ) Intermezzo isn't exactly a blockbuster but expectations are pretty low and there is cash on hand to buy a bit of time to make things happen. FREE MONEY!!
I'm not sure exactly what is wrong with this company. They have a number of good products but can't seem to make a market and are bleeding cash. Under other circumstances, you might see them as buy-out bait, but something just pushes the big boys away. Don't buy.
General Demon haiku (chimpcontest #1 winner, by the grace of God the stock went ratable this morning as it wasn't ratable on the weekend.)Walking-dead groggies Turn'em into pill-poppersSee profits galore
This is my first pitch regarding the subject of one stock in particular. I believe it may interest you if you have not heard of it yet.This pitch will lack the usual good attempt at bad humor - so be forwarned.The company is a small drug developer with a focus on producing the first FDA approved drug to treat the most common type of insomnia - MONI.For the wikipedia description of MONI: http://en.wikipedia.org/wiki/Middle-of-the-Night_InsomniaIn short, people with MONI can fall asleep with no effort, but then wake up after a few hours and can never get back to sleep.Do you ever wonder why people do crazy things - like swerve off the road and hit a tree, or worse, a kid, or fall asleep in somebody else's house (wait was that just being drunk)? Well, according to sleep experts, this stuff is costing many lives every year - thousands of deaths in the U.S. alone. If you are not aware of how far people with severe, chronic insomnia will go for relief - just think of Michael Jackson. He was willing to risk death! I can relate because I suffer from this - and I have tried all of the current medications (Tylenol PM, Ambien and the like have no effect).Regarding the stock:The possible good:Lots of cash for the approval process.Huge potential market (millions of sufferers in the US alone)The FDA's latest concern regarding safety (possible zombie driving accidents) is workable and can be managed (my personal opinion) - the solutions will be accepted by the insomniacs as a fair trade-off for the huge benefit. I envision lock boxes for car keys with a code that has to be entered (assuring the person is awake).The possible bad:The FDA may not ever approve the product. (No gurantee with any new drugs, of course)Another company that I don't know about may be working on a superior product.Additional adverse side effects may surface.Company management could fumble.zzlangerhans has greened thumbed the stock but has suggested people sell prior to final FDA decision. I probably will hold into the decision though (ha what a sucker, you say?)Disclosure - Long TSPTSo what do you think? Did I put you to sleep?
Intermezzo will most definitely get FDA approval. Product has a large market share in the US ($250m est./yr) and in Europe (Estimated half of US sales)Company has $6/share in equity and are planning to buy smaller bio companies to expand its revenue. I am going long for this one. It should be in the 20's within 30 days.
promising research. No product out yet but about to get FDA approval and possibly get acquired by somebody.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions